The drug’s developer, R-Pharm, claims that a clinical trial involving mild or medium-level cases has shown the drug to be highly effective in inhibiting replication of the virus.
After weeks of research in the fight against coronavirus around the world, potential medications are starting to be tested. In Russia, the Defense Ministry has chosen 50 volunteers for clinical trials of a new Covid-19 vaccine.
“The use of levilimab at the very beginning of clinical manifestations of respiratory failure helps prevent the necessity to transfer patients to the intensive care unit.”
In Chekhonin’s opinion, a vaccine against COVID-19 should be expected by the start of the next year.